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from first day of chemotherapy to death of any cause) were 
evaluated. 
Results: A total of 43 patients were included. The median 
follow-up was 45 months (range 6-105 months). Five year 
DFS, PFS and OS were 90%, 76% and 86% respectively. On 
post-chemotherapy PET, CR was seen in 35 patients (81%), 
partial response in three patients (7%) and progression in five 
patients (12%).  
Of the patients with CR, three patients (9%) relapsed, all in 
initial sites of disease with one patient also relapsing in new 
sites. Three of four patients with bulky disease (defined as a 
single nodal mass of 10cm or greater) received consolidative 
RT and none of these patients relapsed. Five year OS for 
patients with PET CR was 94%. Two patients died, one from 
progressive disease and one from bleomycin-related lung 
toxicity. 
Conclusions: Advanced stage HL with PET CR following ABVD 
chemotherapy is associated with an excellent prognosis. 
Relapses were low and occurred in both initial and new sites. 
The use of consolidative RT for bulky disease provided good 
disease control, with no relapses observed.  
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Purpose/Objective: Stereotactic radiosurgery (SRS) is an 
alternative to post-operative whole brain radiation therapy 
(WBRT) following resection of brain metastases. At our 
institution, CyberKnife (CK) is generally used for local 
treatment of larger cavities. In this study, we aimed to 
evaluate patterns of failure with this approach and assess 
whether size of lesion correlated with local failure. 
Materials and Methods: We retrospectively reviewed 30 
patients treated with CK to 33 lesions between 2011-2014. 
Both the cavity resection volume (GTV) and CK treatment 
volume (PTV) were analyzed on treatment planning MRI for 
all cases. Patterns of intracranial control were analyzed in 26 
patients with post-treatment imaging. Survival was estimated 
by the Kaplan Meier method and prognostic factors for local 
and distant control were examined with Fisher’s exact test. 
Results: The most common histologies were lung (42%), 
breast (21%), and melanoma (15%). The cohort was evenly 
split by gender and generally RPA I (33%) and RPA II (57%). 
Median preoperative diameter was 3.3cm and 57% of patients 
underwent gross total resection. Median cavity volume was 
17.5cm3 (range 2.4-69.8 cm3) and median treatment volume 
was 25.11cm3 (range 4.7-90.9cm3). Treatments were 
delivered to a median 30 Gy in 5 fractions to the 75% isodose 
line. Synchronous metastases were treated at the time of CK 
in 33% of cases. The median clinical follow up for the 13 
living patients was 16.9 months (range 4.4-35.2) and for the 
entire cohort of 30 patients was 9.5 months (range 1.0-34.3). 
Local failure developed in 7 treated cavities (23%) and 
median time to local failure was not reached. Patients with 
lung primaries were found to fail locally in five of twelve 
cases (42%) compared to two of 17 (12%) non lung histologies 
(p=0.092). Evaluation of both cavity volume and CK 
treatment volume at a variety of cut-off points showed no 
association with local failure and size (p>0.61 and 0.64, 
respectively). Distant brain failure occurred in 20 cases (63%) 
at a median of 4.6 months. Distant failure developed in eight 
of nine patients with synchronous metastases (89%) compared 
to 11 of 20 without synchronous metastases (56%) (p=0.107). 
Salvage therapies included WBRT (23%) performed at a 
median of 5.1 months from treatment and additional SRS 
(40%) at a median of 4.9 months from treatment. 
Leptomeningeal carcinomatosis developed in 12 cases (40%). 
Patients survived a median of 10.1 months from the time of 
treatment. 
Conclusions: This study suggests that large resection cavities 
are likely to achieve equivalent local control as smaller 
resection beds using adjuvant CK strategy. However, patients 
with lung primaries appear more likely to fail within this 
cohort. Most patients do develop intracranial failure which 
was correlated with synchronous metastases at the time of 
CK. The majority of patients with large cavity volumes were 
spared or delayed WBRT with the use of local CK therapy.  
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Purpose/Objective: The most common site of relapse in 
muscoloskeletal sarcomas is lung. Metastasectomy is 
considered the standard of care in these patients (pts). In 
those unfit for surgery SBRT might represent however an 
alternative approach. The purpose of this study is to evaluate 
local control and toxicity of SBRT in a group of pts treated for 
lung metastases (LM) from bone and soft tissue sarcomas. 
Materials and Methods: From October 2010 to July 2014, 24 
pts with LM from sarcomas not amenable to surgery were 
treated with daily cone beam CT guided SBRT. 22 of them 
had already been submitted at least once to thoracic surgery 
procedures, and 16 pts had been treated with several lines of 
chemotherapy. In 50% of pts the primary tumor was a soft 
tissue sarcoma and in 50% a bone sarcoma (Ewing sarcoma: 5 
pts; osteosarcoma: 3 pts; chondrosarcoma: 4 pts). 21% of pts 
had LM at diagnosis whereas 79% developed LM at a mean of 
39,9 months after initial diagnosis. 71 lesions were treated 
with SBRT. All patients underwent computed tomography 
simulation. Active breath control (ABC©) was employed to 
reduce internal margin in lesions located in the lower lobes. 
Dose was prescribed to 80% isodose. Administered dose 
ranged from 30 to 60 Gy in 3-8 fractions. Follow-up (fu) 
included physical examination and a chest CT scan +/- FDG 
PET/CT every 3 months after treatment. Response rates were 
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scored according to the PERCIST guidelines and for acute and 
late toxicity the CTCAE version 4.0 was used. 
Results: The mean and median fu after SBRT are 12,4 months 
and 8 months respectively. Local control (LC), defined as the 
absence of progression in the treated sites was 79% and 
ranged from 97,7% in lesions < 10 cc to 50% in lesions > 50cc. 
21/24 pts are alive, 6 of them at more than 1 year from 
SBRT. The main cause of failure was the appearance of new 
lung metastases (14/24). Median OS was 8 mos. No pt 
experienced acute G3 toxicity. 4 pts presented a grade 2 
acute lung toxicity and 2 pts hemoptysis in the days following 
SBRT, which receded spontaneously in both cases. One 
patients presented a rib fracture 19 months after SBRT. 
Conclusions: SBRT is a safe and effective treatment for LM 
from sarcoma and might be used as an alternative option in 
pts unfit for surgery. Local control is related to the volume of 
the lesion (< 10 cc: LC 97,7%; > 50 cc: LC 50%). 
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Purpose/Objective: Primary intradural extramedullary Ewing 
sarcoma (PIEES) is morphologically similar to central 
primitive neuroectodermal tumors (cPNET), but is generally 
treated with Ewing sarcoma systemic therapy and focal 
radiotherapy rather than craniospinal radiotherapy, which is 
standard of care for cPNET. The goal of this report is to 
determine the patterns of failure and optimal radiotherapy 
target volumes for PIEES. 
Materials and Methods: The Mayo Clinic tumor registry was 
utilized to identify all Ewing sarcoma of the spine. Only 
patients diagnosed after 1992, when Ewing translocation 
analysis and MRI became routinely available, were included. 
A retrospective chart review was performed to identify 
intradural extramedullary tumors. A PubMed search was 
performed using combinations of the keywords Ewing 
sarcoma, intradural, extramedullary and cauda equina. Only 
reports including radiotherapy (RT) dose and target volume 
and follow-up were included in the analysis. 
Results: Tumor registry review identified 25 patients with 
Ewing sarcoma of the spine, of which 4 patients had PIEES at 
the cervical, thoracic or lumbar levels. All four patients were 
male, age 25 - 60 years old. All patients were treated with 
the Ewing chemotherapy regimen vincristine, doxorubicin, 
cyclophosphamide, ifosfamide and etoposide (VDC/IE); 
however one did not receive cyclophosphamide. Two 
patients, one with lumbar disease and the other with 
thoracic disease, were treated with focal radiation to a dose 
of 50.4 Gy. Both recurred outside of the RT volume, but 
within the craniospinal axis at 4 and 41 months after 
completing therapy, and have subsequently died. One patient 
received craniospinal RT to a total dose of 36 Gy with an 
additional 18 Gy to the primary disease, and is without 
evidence of disease 16 months from the end of therapy. The 
fourth patient is currently under treatment with a planned 30 
Gy to the craniospinal axis and 59.4 Gy to the primary 
disease. 
The literature review identified 10 case reports that met 
criteria. Tumor locations included 2 cervical, 1 thoracic to 
sacral, 4 lumbar and 3 lumbosacral. Six patients were male 
and 4 female with ages ranging from 10 - 60 years old. All 
patients received Ewing –type systemic chemotherapy and 
focal radiation, with a total dose ranging from 30 - 56 Gy. 
Four of the 10 patients experienced distant craniospinal axis 
failure, and one additional patient experienced local failure. 
Median time to recurrence was 8 months (range of 4-31 
months). Two of the 4 patients with craniospinal recurrence 
have died at 14 and 48 months from diagnosis. The patient 
with local recurrence also died 12 months after diagnosis. 
Conclusions: RT appears to provide excellent local control 
with only 1 of 14 patients experiencing local failure, 
however, 6 of 12 patients treated with focal RT experienced 
distant craniospinal axis failure. Craniospinal radiotherapy 
should be considered to improve long-term outcomes in this 
rare tumor.  
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Purpose/Objective: To show our experience, analyse 
different prognosis factor and to compare our results with 
the literature. 
Materials and Methods: Data from 40 consecutive adult 
patients, who were treated between December of 1997 and 
December of 2012, were retrospectively analysed. All of 
them underwent head frame stereotactic radiosurgery (SRS) 
with LINAC as primary, adjuvant or salvage treatment for 
glomus tumours. Tumour and clinical control was calculated 
using the Kaplan-Meier method. Bivariate statistical analyses 
were performed to examine different prognosis factor, using 
logistic regression analyses. 
Results: The median of follow-up was 71 months. The 
radiological local control and clinical control was achieved in 
37 patients (92.5%) and in 29 patients (72.5%) respectively. 
Toxicity was detected in 4 patients (10%) with new symptoms 
related to impairment of V, VIII and X cranial par. In the 
bivariate analysis, dose coverage and maximum dose were 
associated with tumor control with an OR of 5.29 (p=0.041) 
and 2.67 (p=0.056) respectively. 
Conclusions: SRS is a safe and efficacious treatment for 
glomus tumours that is associated with high probability of 
radiological and clinical control and low incidence of 
morbidity. 
